$EGRX
EAGLE PHARMACEUTICALS, INC.

2017 Q4 Form 10-Q Financial Statement

#000082787117000010 Filed on November 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2016 Q3
Revenue $46.79M $63.02M $37.83M
YoY Change -42.34% 66.58% 559.57%
Cost Of Revenue $13.71M $4.815M $10.43M
YoY Change -27.15% -53.81% 177.78%
Gross Profit $33.08M $58.21M $27.41M
YoY Change -46.92% 112.37% 1282.15%
Gross Profit Margin 70.71% 92.36% 72.44%
Selling, General & Admin $13.32M $16.67M $11.66M
YoY Change -23.4% 42.95% 113.57%
% of Gross Profit 40.27% 28.64% 42.55%
Research & Development $9.440M $8.954M $3.207M
YoY Change -43.3% 179.2% -53.6%
% of Gross Profit 28.54% 15.38% 11.7%
Depreciation & Amortization $950.0K $950.0K $360.0K
YoY Change 41.79% 163.89% 3500.0%
% of Gross Profit 2.87% 1.63% 1.31%
Operating Expenses $22.63M $38.07M $25.53M
YoY Change -33.52% 49.15% 58.3%
Operating Profit $10.44M $24.95M $12.31M
YoY Change -63.08% 102.71% -218.48%
Interest Expense -$500.0K $527.0K $3.000K
YoY Change -5100.0% 17466.67% -40.0%
% of Operating Profit -4.79% 2.11% 0.02%
Other Income/Expense, Net -$492.0K $23.00K
YoY Change -2239.13% 666.67%
Pretax Income $9.940M $24.46M $12.33M
YoY Change -64.86% 98.35% -218.74%
Income Tax -$2.550M $9.027M $379.0K
% Of Pretax Income -25.65% 36.91% 3.07%
Net Earnings $9.090M $15.43M $11.95M
YoY Change -84.14% 29.11% -217.56%
Net Earnings / Revenue 19.43% 24.49% 31.59%
Basic Earnings Per Share $0.61 $1.03 $0.77
Diluted Earnings Per Share $0.58 $0.98 $0.73
COMMON SHARES
Basic Shares Outstanding 14.92M shares 15.05M shares 15.57M shares
Diluted Shares Outstanding 15.76M shares

Balance Sheet

Concept 2017 Q4 2017 Q3 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $114.7M $97.50M $59.30M
YoY Change 117.23% 64.42% -38.23%
Cash & Equivalents $114.7M $97.55M $59.31M
Short-Term Investments
Other Short-Term Assets $561.0K $850.0K $426.0K
YoY Change 58.03% 99.53% 167.92%
Inventory $5.118M $4.878M $7.106M
Prepaid Expenses
Receivables $53.82M $71.60M $47.05M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $188.7M $182.2M $119.0M
YoY Change 72.94% 53.01% -1.04%
LONG-TERM ASSETS
Property, Plant & Equipment $6.820M $4.365M $2.827M
YoY Change 105.67% 54.4% 56.79%
Goodwill $39.74M $39.74M
YoY Change 0.0%
Intangibles $23.32M $24.00M $24.76M
YoY Change -30.12% -3.06%
Long-Term Investments
YoY Change
Other Assets $124.0K $124.0K $94.00K
YoY Change -8.82% 31.91% -15.32%
Total Long-Term Assets $81.36M $84.74M $27.68M
YoY Change -22.67% 206.13% 1346.19%
TOTAL ASSETS
Total Short-Term Assets $188.7M $182.2M $119.0M
Total Long-Term Assets $81.36M $84.74M $27.68M
Total Assets $270.1M $266.9M $146.7M
YoY Change 26.01% 81.9% 20.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $11.98M $8.902M $13.10M
YoY Change -18.59% -32.07% -7.38%
Accrued Expenses $15.39M $20.44M $21.33M
YoY Change -39.01% -4.19% 47.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $4.875M $5.000M
YoY Change
Total Short-Term Liabilities $47.30M $34.40M $35.45M
YoY Change 15.47% -2.97% 2.49%
LONG-TERM LIABILITIES
Long-Term Debt $42.91M $43.94M $0.00
YoY Change
Other Long-Term Liabilities $700.0K $17.50M $5.800M
YoY Change -96.83% 201.72%
Total Long-Term Liabilities $42.91M $43.94M $5.800M
YoY Change 657.52%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.30M $34.40M $35.45M
Total Long-Term Liabilities $42.91M $43.94M $5.800M
Total Liabilities $90.21M $78.33M $41.20M
YoY Change 120.21% 90.12% 19.08%
SHAREHOLDERS EQUITY
Retained Earnings $26.28M $17.20M -$82.96M
YoY Change -202.44% -120.73% -23.42%
Common Stock $16.00K $16.00K $15.00K
YoY Change 0.0% 6.67% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $80.80M $75.79M $18.00M
YoY Change 118.35% 321.14%
Treasury Stock Shares 1.242M shares 1.150M shares 290.6K shares
Shareholders Equity $179.1M $171.1M $105.5M
YoY Change
Total Liabilities & Shareholders Equity $270.1M $266.9M $146.7M
YoY Change 26.01% 81.9% 20.05%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2016 Q3
OPERATING ACTIVITIES
Net Income $9.090M $15.43M $11.95M
YoY Change -84.14% 29.11% -217.56%
Depreciation, Depletion And Amortization $950.0K $950.0K $360.0K
YoY Change 41.79% 163.89% 3500.0%
Cash From Operating Activities $25.92M $7.890M $13.17M
YoY Change -34.48% -40.09% -298.34%
INVESTING ACTIVITIES
Capital Expenditures -$2.730M -$1.580M -$14.18M
YoY Change 259.21% -88.86% 1225.23%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$2.730M -$1.580M -$14.18M
YoY Change -90.12% -88.86% -121.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -6.080M 35.84M -15.24M
YoY Change -67.01% -335.17%
NET CHANGE
Cash From Operating Activities 25.92M 7.890M 13.17M
Cash From Investing Activities -2.730M -1.580M -14.18M
Cash From Financing Activities -6.080M 35.84M -15.24M
Net Change In Cash 17.11M 42.15M -16.25M
YoY Change -363.64% -359.38% -127.88%
FREE CASH FLOW
Cash From Operating Activities $25.92M $7.890M $13.17M
Capital Expenditures -$2.730M -$1.580M -$14.18M
Free Cash Flow $28.65M $9.470M $27.35M
YoY Change -28.94% -65.37% -591.02%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
0 USD
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.32
CY2017Q3 egrx License Agreement Proceeds From Upfront Payment
LicenseAgreementProceedsFromUpfrontPayment
12500000 USD
dei Document Period End Date
DocumentPeriodEndDate
2017-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000827871
CY2017Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14921623 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
EAGLE PHARMACEUTICALS, INC.
CY2016Q4 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
2856000 USD
CY2016Q4 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
3528000 USD
CY2016Q4 egrx Advancestocommercialmanufactures
Advancestocommercialmanufactures
7600000 USD
CY2017Q3 egrx Advancestocommercialmanufactures
Advancestocommercialmanufactures
4631000 USD
CY2017Q3 egrx Clinical Development Cost Sharing Percentage
ClinicalDevelopmentCostSharingPercentage
0.5
CY2017Q3 egrx Finite Lived Intangible Assets Impairment
FiniteLivedIntangibleAssetsImpairment
7235000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
3713000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
-3227000 USD
CY2017Q3 egrx Number Of Products
NumberOfProducts
5 product
egrx Paymentsfor Contingent Consideration
PaymentsforContingentConsideration
230000 USD
egrx Paymentsfor Contingent Consideration
PaymentsforContingentConsideration
0 USD
CY2016Q4 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1592000 USD
CY2017Q3 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
0 USD
CY2016Q4 egrx Prepaid Research And Development
PrepaidResearchAndDevelopment
21000 USD
CY2017Q3 egrx Prepaid Research And Development
PrepaidResearchAndDevelopment
166000 USD
egrx Repurchase Of Common Stock Not Yet Paid
RepurchaseOfCommonStockNotYetPaid
1500000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14716000 USD
CY2017Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8902000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
42194000 USD
CY2017Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
71601000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25237000 USD
CY2017Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
20438000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2094000 USD
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9068000 USD
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
6003000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
213872000 USD
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
229655000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11618000 USD
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2250000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7539000 USD
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3728000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11618000 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0 USD
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
128000 USD
CY2016Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
201000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
461000 USD
CY2017Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
711000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2135000 USD
CY2016Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1387997 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1375351 shares
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1671570 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1580277 shares
CY2016Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2017Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
7235000 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
7235000 USD
CY2016Q4 us-gaap Assets
Assets
214320000 USD
CY2017Q3 us-gaap Assets
Assets
266890000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
109110000 USD
CY2017Q3 us-gaap Assets Current
AssetsCurrent
182154000 USD
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
6370000 USD
CY2016Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
232000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
627000 USD
CY2017Q3 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-6452000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-5604000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1012000 USD
CY2017Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
55000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
22129000 USD
CY2017Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
17482000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79083000 USD
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59311000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52820000 USD
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
97545000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-19772000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
44725000 USD
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15890862 shares
CY2017Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16071435 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2017Q3 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2016Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
6000000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
25949000 USD
CY2017Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
4815000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
24490000 USD
CY2017Q3 us-gaap Deferred Finance Costs Noncurrent Gross
DeferredFinanceCostsNoncurrentGross
1100000 USD
CY2016Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
28643000 USD
CY2017Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
16502000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
0 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
12141000 USD
us-gaap Depreciation
Depreciation
461000 USD
us-gaap Depreciation
Depreciation
657000 USD
CY2016Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.77
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.55
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.82
CY2016Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.46
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
2.68
CY2016Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.03
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.04
CY2017Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.37
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
948000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3083000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
12019000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
628000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
2910000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2953000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2807000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2685000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
34320000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
34320000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
33372000 USD
CY2017Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
24002000 USD
CY2016Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1750000 USD
CY2017Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2016Q4 us-gaap Goodwill
Goodwill
39743000 USD
CY2017Q3 us-gaap Goodwill
Goodwill
39743000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2016Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12331000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
25135000 USD
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
24458000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
63006000 USD
CY2016Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
379000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
983000 USD
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9027000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20148000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
2800000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
8845000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7747000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5814000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20783000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
29407000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3074000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4049000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6000000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-7936000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2139000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-49000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-12000 USD
CY2016Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
879442 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
886839 shares
CY2017Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
716443 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
840625 shares
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
33372000 USD
CY2017Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
24002000 USD
CY2016Q3 us-gaap Interest Expense Other
InterestExpenseOther
3000 USD
us-gaap Interest Expense Other
InterestExpenseOther
6000 USD
CY2017Q3 us-gaap Interest Expense Other
InterestExpenseOther
527000 USD
us-gaap Interest Expense Other
InterestExpenseOther
594000 USD
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
708000 USD
CY2017Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2617000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
2739000 USD
CY2017Q3 us-gaap Inventory Net
InventoryNet
4878000 USD
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1131000 USD
CY2017Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1833000 USD
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
900000 USD
CY2017Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
428000 USD
CY2016Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
26000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
76000 USD
CY2017Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
35000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
52000 USD
CY2016Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
145000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
463000 USD
CY2017Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
184000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
503000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
214320000 USD
CY2017Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
266890000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40965000 USD
CY2017Q3 us-gaap Liabilities Current
LiabilitiesCurrent
34395000 USD
CY2016Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2017Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
5000000 USD
CY2017Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
43936000 USD
CY2016Q1 us-gaap Loss Contingency Patents Allegedly Infringed Number
LossContingencyPatentsAllegedlyInfringedNumber
2 patent
CY2016Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3104000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
8825000 USD
CY2017Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
2568000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
17296000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-15241000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14183000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18183000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2456000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
13652000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
32998000 USD
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
11952000 USD
us-gaap Net Income Loss
NetIncomeLoss
24152000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
15431000 USD
us-gaap Net Income Loss
NetIncomeLoss
42858000 USD
CY2016Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
11952000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
24152000 USD
CY2017Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
15431000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
42858000 USD
CY2016Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
23000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
70000 USD
CY2017Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-492000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-542000 USD
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
25525000 USD
us-gaap Operating Expenses
OperatingExpenses
83276000 USD
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
38071000 USD
us-gaap Operating Expenses
OperatingExpenses
126374000 USD
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
12308000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
25065000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
24950000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
63548000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2661000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
117000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
395000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
674000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
670000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
638000 USD
CY2017Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
167000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1688000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
355000 USD
CY2017Q3 us-gaap Other Assets Current
OtherAssetsCurrent
850000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
136000 USD
CY2017Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
124000 USD
CY2016Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
3750000 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
9750000 USD
CY2017Q3 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
12500000 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
37500000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
16497000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
38790000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1192000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
4850000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
14000000 USD
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
750000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1083000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1706000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
62000000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2017Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11357000 USD
CY2017Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8130000 USD
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
135000 USD
CY2017Q3 us-gaap Prepaid Insurance
PrepaidInsurance
307000 USD
CY2016Q4 us-gaap Prepaid Taxes
PrepaidTaxes
1654000 USD
CY2017Q3 us-gaap Prepaid Taxes
PrepaidTaxes
2176000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
6500000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
50000000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
62000000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
0 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1750000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1486000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4165000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3316000 USD
CY2017Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4365000 USD
CY2017Q3 us-gaap Purchase Obligation
PurchaseObligation
17895000 USD
CY2017Q3 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
0 USD
CY2017Q3 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
0 USD
CY2017Q3 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 USD
CY2017Q3 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 USD
CY2017Q3 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 USD
CY2017Q3 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
17895000 USD
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3207000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13612000 USD
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8954000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23163000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25659000 USD
CY2017Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
17199000 USD
CY2016Q3 us-gaap Royalty Expense
RoyaltyExpense
4425000 USD
us-gaap Royalty Expense
RoyaltyExpense
10538000 USD
CY2017Q3 us-gaap Royalty Expense
RoyaltyExpense
6850000 USD
us-gaap Royalty Expense
RoyaltyExpense
18990000 USD
CY2016Q3 us-gaap Royalty Revenue
RoyaltyRevenue
26246000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
67025000 USD
CY2017Q3 us-gaap Royalty Revenue
RoyaltyRevenue
43616000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
117527000 USD
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
7837000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
31566000 USD
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
6905000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
34895000 USD
CY2016Q3 us-gaap Sales Revenue Net
SalesRevenueNet
37833000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
108341000 USD
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16669000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
58100000 USD
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q3 us-gaap Sales Revenue Net
SalesRevenueNet
63021000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
189922000 USD
CY2016Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11661000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34300000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0190
us-gaap Share Based Compensation
ShareBasedCompensation
7539000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
11618000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3168
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3134
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3448
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3691
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0141
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0219
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0242
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0094
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0094
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0170
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0170
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4165000 USD
CY2016Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
75000000.0 USD
CY2017Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
100000000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
151226000 USD
CY2017Q3 us-gaap Stockholders Equity
StockholdersEquity
171077000 USD
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
566838 shares
CY2017Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
1150437 shares
CY2016 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
566838 shares
CY2017Q3 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
583599 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
583599 shares
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
37003000 USD
CY2017Q3 us-gaap Treasury Stock Value
TreasuryStockValue
75793000 USD
CY2016 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
37000000 USD
CY2017Q3 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
38790000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
38800000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
38790000 USD
CY2017Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2016Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16450182 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16501167 shares
CY2017Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
15764360 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16015051 shares
CY2016Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15570740 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15614328 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15047917 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15174426 shares
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2016 was derived from audited financial statements, but certain information and footnote disclosures normally included in the Company's annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made.&#160;Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 15, 2017. Unless otherwise indicated or required by context, reference throughout to the "Company," "Eagle Pharmaceuticals," "Eagle," "we," "us" or "our" mean Eagle Pharmaceuticals, Inc., a Delaware corporation and its subsidiary, Eagle Biologics, Inc., and references to "Eagle Biologics" mean Eagle Biologics, Inc.</font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name View Source Status
0000827871-17-000010-index-headers.html Edgar Link pending
0000827871-17-000010-index.html Edgar Link pending
0000827871-17-000010.txt Edgar Link pending
0000827871-17-000010-xbrl.zip Edgar Link pending
egrx-20170930.xml Edgar Link completed
egrx-20170930.xsd Edgar Link pending
egrx-20170930_cal.xml Edgar Link unprocessable
egrx-20170930_def.xml Edgar Link unprocessable
egrx-20170930_lab.xml Edgar Link unprocessable
egrx-20170930_pre.xml Edgar Link unprocessable
egrx_q3x2017.htm Edgar Link pending
exhibit102q32017.htm Edgar Link pending
exhibit311q32017.htm Edgar Link pending
exhibit312q32017.htm Edgar Link pending
exhibit321q32017.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
redactedeaglesymbioli_image1.gif Edgar Link pending
redactedeaglesymbioli_image2.gif Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending